Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 56-17 IMpassion 

This is a global Phase III, open-label, randomized, controlled study designed to evaluate the efficacy, safety, and pharmacokinetics of adjuvant treatment with atezolizumab +T-AC compared with T-AC alone in patients with newly diagnosed triple-negative breast cancer who have had curativintent of their primary tumor and are candidates for adjuvant systemic therapy following surgery.

DESIGN

please click on the picture to see a larger version

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Poonam Jani


IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email:
ibcsg56_IMpassion@fstrf.org


IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email:
xx

Targeted Accrual
2300


News

09.09.2018:
9.9.2018 - RACE FOR LIFE, Bundesplatz Bern

19.06.2018:
PINK GOLFTOUR 2018  

10.06.2018:
32. SCHWEIZER FRAUENLAUF woman 4 woman - walking together, stronger than ever

All News

 
  Print